CLEVELAND, OH — Researchers are warning about "unexpectedly" and "abruptly" increased rates of thrombosis with the HeartMate II (Thoratec) left ventricular assist device (LVAD) occurring early after ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

Fourteen people have died and 273 have been injured as a result of biological material building up over time in the grafts connecting both HeartMate II and HeartMate 3 left ventricular assist device ...

The HeartMate II LVAD is being studied in the ROADMAP postmarket study. Thoratec presented one-year results from its real-world study, ROADMAP, at the annual meeting of the International Society for ...

NEW YORK (April 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate® II LVAS (Left ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...

The long-term use of ventricular assist devices is becoming a problem for at least some of these devices, as demonstrated by the recall of the Heartmate II and Heartmate 3 devices by Abbott ...

Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun enrollment in the SHIELD ...

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for ...

Trialists and journalists, practitioners and bloggers really appreciate a soundly positive trial. MOMENTUM-3, presented at the American College of Cardiology 2018 Annual Scientific Sessions, fit that ...